Aurobindo to move U.S. HQ, manufacturing to North Carolina


Aurobindo, an Indian generic drugmaker, said it will build its new headquarters for U.S. operations and manufacturing in Durham, NC, bringing $31.7 million in investments and creating 275 jobs.

The announcement is the first such economic development to be unveiled in the state since state lawmakers approved the controversial House Bill 2 that is designed to protect business owners from legal action if they refuse on religious grounds to do business with gay customers, the Triangle Business Journal reported. Musicians have cancelled performances and corporations such as PayPal and Deutsche Bank have backed away from expansion projects in the state because of the law. 

A jobs development grant worth up to $3.8 million over the next 12 years was approved for Aurobindo in addition to $400,000 given in economic incentives by both the city of Durham and Durham County. Another $467,000 in training through the community college system also has been granted to the company.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

With a facility in Durham, Aurobindo will be able to ramp up production faster than if it decided to build a new plant on land it owns in New Jersey. 

“We are excited about our plans for expansion of our specialty pharma R&D and manufacturing in North Carolina,” Dr. Ninad Deshpanday, president of Aurobindo’s U.S. operations, said in a statement.

The company’s expansion into North Carolina is expected to generate a $17.1 million annual payroll, officials said.

In October, Aurobindo announced plans to build three new plants in India in the next three years.

-here’s the Triangle Business Journal story

Related Article:
Aurobindo to expand India API plant fourfold

Pictured is downtown Durham, courtesy of Atlpedia.


Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.